Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 2.01M -55.3% |
| Revenue (ttm) | n/a |
| Net Income | -7.77M |
| EPS | -8.22 |
| Shares Out | 1.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,410 |
| Open | 1.410 |
| Previous Close | 1.440 |
| Day's Range | 1.354 - 1.440 |
| 52-Week Range | 1.354 - 18.900 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 37.50 (+2,559.57%) |
| Earnings Date | May 8, 2026 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for ADIL stock is "Strong Buy" and the 12-month stock price target is $37.5.
News
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for ...
Adial Pharmaceuticals files AD04 utility application with USPTO
Adial Pharmaceuticals (ADIL) announced the filing of a new U.S. utility application with the United States Patent and Trade Office, or USPTO, directed to AD04, the company’s lead investigational genet...
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility...
Adial submits AD04 product application for FDA CNPV pilot program
Adial Pharmaceuticals (ADIL) announced the submission of the AD04 product application for consideration of the FDA Commissioner’s National Priority Voucher Pilot Program. Announced in 2025, the CNPV p...
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatme...
Adial Pharmaceuticals completes AD04 demonstration batch production
Adial Pharmaceuticals (ADIL) announced completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for th...
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product produc...
Adial Pharmaceuticals expects cash to fund operations into 2H of 2026
Cash and cash equivalents were $5.9 million as of December 31, 2025, compared to $3.8 million as of December 31, 2024. The Company believes that its existing cash and cash…
Adial Pharmaceuticals enters collaboration framework agreement with Molteni
Adial Pharmaceuticals (ADIL) announced it has entered into a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive partnership covering the commercialization of AD04 in ...
Adial Pharmaceuticals regains compliance with Nasdaq listing requirement
Adial Pharmaceuticals (ADIL) announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq…
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3
Adial Pharmaceuticals highlights recent FDA policy, may reduce trial burden
Adial Pharmaceuticals (ADIL) highlighted recent U.S. Food and Drug Administration, FDA, policy direction described by FDA Commissioner Martin Makary, M.D., M.P.H., and Vinay Prasad, M.D., M.P.H., in a...
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Subm...
Adial Pharmaceuticals price target lowered to $8 from $37.50 at Maxim
Maxim lowered the firm’s price target on Adial Pharmaceuticals (ADIL) to $8 from $37.50 and keeps a Buy rating on the shares. The firm remains positive on the stock based…
Adial Pharmaceuticals trading halted, news pending
19:50 EST Adial Pharmaceuticals (ADIL) trading halted, news pending
Why Is Adial Pharmaceuticals Stock (ADIL) Down Today?
Adial Pharmaceuticals stock fell on Thursday after the company revealed a reverse stock split.
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals announces 1-for-25 reverse stock split
Adial Pharmaceuticals (ADIL) announced it will effect a 1-for-25 reverse stock split of its common stock, effective February 5 at 11:59 p.m. ET. The stock will begin trading on a…
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026
Adial announces publication of international patent application for AD04
Adial Pharmaceuticals (ADIL) announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the Company’s lead investigational genetically targeted serotonin-3...
Adial Pharmaceuticals announces $2.86M warrant inducement transaction
Adial Pharmaceuticals (ADIL) announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Se...
Adial Pharmaceuticals reports Q3 net loss $1.8M vs $2.2M last year
Cash and cash equivalents were $4.6 million as of September 30, 2025, compared to $5.9 million as of June 30, 2025. The Company believes that its existing cash and cash…
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for...
Adial Pharmaceuticals partners with Genomind for Precision Medicine Testing
Adial Pharmaceuticals (ADIL) announced the successful completion of the analytical validation of a cheek swab collection method for testing patients for both clinical trial usage as well as future com...
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 development Partnership has ...